The aim of the study was to investigate the effects of 20-80 mg/day dose of Nicorandil therapy on cardiac performance in patients with congestive heart failure. A prospective study with a follow up of 12 months was conducted. Twenty patients with ischemic disease and chronic heart failure, from Diagnostic and Treatment Centre, Cluj-Napoca were included into the study. The hemodynamic parameters expressed as ejection fraction, effort tolerance, and clinical simptomatology were improved in the patients treated by Nicorandil. Nicorandil treatment can improve the patients’ life quality, hemodynamic status and it is possible to reduce mortality in congestive heart failure.


Nicorandil, Potassium channel activators, Congestive heart failure, Ischemic heart disease, Cardiac performance.